Piet Ost, Radiation Oncologist at Iridium Network Antwerp, shared a post on X:
“So if we do not see a benefit from Abi in mHSPC pts older than 75 yo, I presume we also won’t see a benefit in pts locally advanced M0 HSPC trials.
The median age in STAMPEDE M0 was 67. What was it in Enzarad/GU009 Paul Nguyen? In Thunder trial, median age is 77 yo.”
Other articles featuring Piet Ost on OncoDaily.